1. Home
  2. BCV vs CDXS Comparison

BCV vs CDXS Comparison

Compare BCV & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bancroft Fund Ltd.

BCV

Bancroft Fund Ltd.

HOLD

Current Price

$23.80

Market Cap

129.4M

Sector

Finance

ML Signal

HOLD

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.83

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BCV
CDXS
Founded
1971
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Major Chemicals
Sector
Finance
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
129.4M
141.8M
IPO Year
N/A
2010

Fundamental Metrics

Financial Performance
Metric
BCV
CDXS
Price
$23.80
$1.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
26.3K
805.0K
Earning Date
01-01-0001
02-26-2026
Dividend Yield
8.13%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$52,932,000.00
Revenue This Year
N/A
$15.64
Revenue Next Year
N/A
$5.23
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$14.09
$1.52
52 Week High
$18.11
$5.43

Technical Indicators

Market Signals
Indicator
BCV
CDXS
Relative Strength Index (RSI) 71.41 58.06
Support Level $23.40 $1.61
Resistance Level $23.89 $1.74
Average True Range (ATR) 0.33 0.08
MACD 0.11 0.02
Stochastic Oscillator 96.16 92.59

Price Performance

Historical Comparison
BCV
CDXS

About BCV Bancroft Fund Ltd.

Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

Share on Social Networks: